Audrey Burban

Audrey Burban

Auto-generated profile, based on publicly available information

Audrey Burban

Univ. Bordeaux, CNRS, IBGC

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
ASAhmad Sharanek
Ahmad Sharanek
ABAudrey Burban
Audrey Burban
LHLydie Humbert
Lydie Humbert
CGChristiane Guguen-Guillouzo
Christiane Guguen-Guillouzo
DRDominique Rainteau
Dominique Rainteau
AGAndré Guillouzo
André Guillouzo
Drug-induced intrahepatic cholestasis is characterized by cellular accumulation of bile acids (BA) whose mechanisms remain poorly understood. The present study aimed to analyze early and progressive alterations of BA profiles induced by cyclosporine A, chlorpromazine, troglitazone, tolcapone, trovafloxacin and tacrolimus after 4h, 24h and 6 daily treatments of differentiated HepaRG cells. In BA-free medium the potent cholestatic drugs, cyclosporine A, chlorpromazine and troglitazone, reduced endogenous BA synthesis after 24h, while the rarely cholestatic drugs, tolcapone, trovafloxacin and tacrolimus, reduced BA synthesis only after 6 days. In the presence of physiological serum BA concentrations, cyclosporine A, chlorpromazine and troglitazone induced early and preferential cellular accumulation of unconjugated lithocholic, deoxycholic and chenodeoxycholic acids that increased 8-12- and 47-50-fold after 24h and 6 days respectively. Accumulation of these hydrophobic BAs resulted from strong inhibition of amidation and in addition, for lithocholic acid reduction of its sulfo-conjugation, and was associated with variable alterations of uptake and efflux transporters. Trovafloxacin also caused BA accumulation, especially after 6 days, while tolcapone and tacrolimus were still without effect. However, when exogenous BAs were added to the medium at cholestatic serum concentrations, a 6-day treatment with all drugs resulted in cellular BA accumulation with higher folds of chenodeoxycholic and lithocholic acids. At the tested concentration, tolcapone had the lowest effect. These results bring the first demonstration that major cholestatic drugs can cause preferential and progressive in vitro cellular accumulation of unconjugated toxic hydrophobic BAs, and bring new insights in mechanisms involved in drug-induced cellular accumulation of toxic BAs.

1 August 2019 in Toxicology in Vitro
Verified
Journal Article
Closed access
ASAhmad Sharanek
Ahmad Sharanek
ABAudrey Burban
Audrey Burban
NCNadia Ciriaci
Nadia Ciriaci
AGAndré Guillouzo
André Guillouzo

3 February 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
ABAudrey Burban
Audrey Burban
CTCloe Tessier
Cloe Tessier
MLMathieu Larroquette
Mathieu Larroquette
JGJoris Guyon
Joris Guyon
CLCloe Lubiato
Cloe Lubiato
ASAhmad Sharanek
Ahmad Sharanek
Glioblastoma is one of the most treatment-resistant and lethal cancers, with a subset of self-renewing brain tumour stem cells (BTSCs), driving therapy resistance and relapse. Here, we report that mubritinib effectively impairs BTSC stemness and growth. Mechanistically, bioenergetic assays and rescue experiments showed that mubritinib targets complex I of the electron transport chain, thereby impairing BTSC self-renewal and proliferation. Gene expression profiling and Western blot analysis revealed that mubritinib disrupts the AMPK/p27 Kip1 pathway, leading to cell-cycle impairment. By employing in vivo pharmacokinetic assays, we established that mubritinib crosses the blood-brain barrier. Using preclinical patient-derived and syngeneic models, we demonstrated that mubritinib delays glioblastoma progression and extends animal survival. Moreover, combining mubritinib with radiotherapy or chemotherapy offers survival advantage to animals. Notably, we showed that mubritinib alleviates hypoxia, thereby enhancing ROS generation, DNA damage, and apoptosis in tumours when combined with radiotherapy. Encouragingly, toxicological and behavioural studies revealed that mubritinib is well tolerated and spares normal cells. Our findings underscore the promising therapeutic potential of mubritinib, warranting its further exploration in clinic for glioblastoma therapy.

4 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CRCedric Rakotovao
Cedric Rakotovao
ASAhmad Sharanek
Ahmad Sharanek
ABAudrey Burban
Audrey Burban
PGPaul Gueroue
Paul Gueroue
SBStéphane Bouchet
Stéphane Bouchet
JGJoris Guyon
Joris Guyon
Therapeutic drug monitoring of protein kinase inhibitors is a widely practiced worldwide. Based on the example of ripretinib dosage requested by a clinician, we detailed the process of method development, using a literature-based approach while ensuring the sustainability of the method to be as environmentally friendly as possible. Therefore, an UPLC-MS/MS method for ripretinib and its active metabolite was optimized and validated using the corresponding stable isotopic internal standards in human plasma. The procedure has employed mobile phase mixture of water with 1% acetic acid and 0.1% formic acid, and acetonitrile. Positive electrospray ionization was performed coupling with multiple reaction monitoring of m/z 510.4→417.4 and 510.4→389.4 for ripretinib, and 496.3→403.3 and 496.3→375.3 for N-desmethyl-ripretinib. The method was successfully validated according the current version of ICH Guideline provided by the EMA. The greenness assessment score of this procedure was evaluated and compared with previously published approaches using the AGREE metric. The validated UPLC-MS/MS method successfully monitored ripretinib and its metabolite concentrations in clinical and pre-clinical models.